Abstract
Available treatments are inadequate for many elderly patients with acute myeloid leukaemia (AML) who are considered by their physician to be unfit for intensive chemotherapy—at least 80% of patients die within 1 year of diagnosis. Findings from cancer registry studies suggest that up to 70% of patients are not offered any treatment other than best supportive care.1 In The Lancet Oncology, Hagop Kantarjian and colleagues report the findings from their randomised phase 2 study of three different dose schedules of the novel oral cytosine nucleoside analogue, sapacitabine, in elderly patients with AML who were either treatment-naive or at first relapse.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
